Compare AbbVie Inc (ABBV) vs Twilio Inc (TWLO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Twilio Inc — how do they compare? AbbVie Inc trades at $253.79 (market cap $449.91B), while Twilio Inc trades at $212.91 (market cap $32.17B). The key difference: AbbVie Inc is far larger — about 14× Twilio Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Twilio Inc pays none. Which is the better fit depends on your goals.
| ABBV | TWLO | |
|---|---|---|
Market Cap | $449.91B | $32.17B |
Sector | Health | Technology |
52-Week High | $261.07 | $236.64 |
52-Week Low | $184.85 | $92.44 |
Enterprise Value | $513.38B | $30.89B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Twilio (TWLO) trades at $211.97, up 1.27% with bullish technical signals and strong analyst support. The stock shows improving fundamentals with revenue growth from $4.5B to $5.1B in 2025 and a return to profitability after years of losses. Recent earnings beats and AI-driven demand for cloud communications tools support positive momentum. Technical indicators show the stock trading near pivot point resistance at $210 with bullish moving average alignment.
Twilio presents a growth opportunity with margin expansion potential and AI adoption driving demand, though elevated valuation metrics (P/E 316.79) warrant caution. Key risks include competitive pressures in cloud communications and execution challenges in maintaining profitability growth. Analyst consensus remains strongly bullish with 75% buy ratings and $211.69 price target, suggesting balanced risk-reward near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
